Belvedere Trading
BBH icon

Belvedere Trading’s VanEck Biotech ETF BBH Stock Holding History

Belvedere Trading’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$183K Sell
900
-1,000
-53% -$188K ﹤0.01% 612
2026
Q1 		$357K Buy
+1,900
New +$366K ﹤0.01% 301
2025
Q2 		– Sell
-3,000
Closed -$472K – 832
2025
Q1 		$472K Buy
+3,000
New +$487K ﹤0.01% 201

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CCA
Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Belvedere Trading's BBH Position: Q2 2026 in Review

Belvedere Trading increased its VanEck Biotech ETF (BBH) stake by 83% in Q2 2026, buying an estimated $95.2K and bringing the position to 1,112 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Belvedere Trading first reported a position in BBH in Q1 2026 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

  • Belvedere Trading held 1,112 shares of VanEck Biotech ETF worth $226K as of Q2 2026.
  • Belvedere Trading bought 506 VanEck Biotech ETF shares in Q2 2026, an estimated $95.2K.
  • VanEck Biotech ETF made up ﹤0.01% of Belvedere Trading's portfolio in Q2 2026, its #543 holding.
  • Belvedere Trading first reported a position in VanEck Biotech ETF in Q1 2026 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Belvedere Trading's 13F filing for Q2 2026, filed 31 Jul 2026.